NICHOLE FLEMING: Open Payments
NPI 1871998518 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,249 in 64 payments from 11 companies in 2025. Trend: 2023 $1,383 · 2024 $963 · 2025 $1,249
Food & beverage: $1,249
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 23 | $604 |
| Celltrion USA Inc. | 20 | $202 |
| Lilly USA, LLC | 3 | $74 |
| Janssen Biotech, Inc. | 4 | $71 |
| Ardelyx, Inc. | 3 | $61 |
| GENZYME CORPORATION | 2 | $54 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $52 |
| Ipsen Biopharmaceuticals, Inc | 2 | $50 |
| Aimmune Therapeutics, Inc. | 2 | $30 |
| ABBVIE INC. | 1 | $30 |
Products named: VELSIPITY, VEGZELMA, OMVOH, TREMFYA, IBSRELA, DUPIXENT, XIFAXAN, IQIRVO.
Industry payments across TX — which companies pay providers there.
